McCabe Sean Esteban, Veliz Philip, Boyd Carol J, Schulenberg John E
University of Michigan, Institute for Research on Women and Gender, Substance Abuse Research Center, Ann Arbor 48109, MI, USA.
University of Michigan, Institute for Research on Women and Gender, Ann Arbor 48109, MI, USA.
Addict Behav. 2017 Feb;65:296-301. doi: 10.1016/j.addbeh.2016.08.021. Epub 2016 Aug 15.
This study assessed the longitudinal associations between medical and nonmedical use of prescription sedatives/anxiolytics (NMPSA) during adolescence (age 18) and substance use disorder (SUD) symptoms during adulthood (age 35).
Multiple cohorts of nationally representative samples of U.S. high school seniors (n=8373) were surveyed via self-administered questionnaires and followed longitudinally from adolescence (age 18, 1976-1996) to adulthood (age 35, 1993-2013).
An estimated 20.1% of adolescents reported lifetime medical or nonmedical use of prescription sedatives/anxiolytics. Among adolescents who reported medical use of prescription sedatives/anxiolytics, 44.9% also reported NMPSA by age 18. Based on multivariate analyses that included age 18 sociodemographic and other substance use controls, medical use of prescription sedatives/anxiolytics without any history of NMPSA during adolescence was not associated with SUD symptoms in adulthood relative to adolescents with no prescription sedative/anxiolytic use. In contrast, adolescents with a history of both medical and nonmedical use of prescription sedatives/anxiolytics and adolescents who reported only NMPSA had between two to three times greater odds of SUD symptoms in adulthood relative to adolescents with no prescription sedative/anxiolytic use and those who reported only medical use of prescription sedatives/anxiolytics.
One in every five U.S. high school seniors reported ever using prescription sedatives/anxiolytics either medically or nonmedically. This study provides compelling evidence that the medical use of prescription sedatives/anxiolytics (without any NMPSA) during adolescence is not associated with increased risk of SUD symptoms in adulthood while any NMPSA during adolescence serves as a signal for SUDs in adulthood.
本研究评估了青少年期(18岁)使用处方镇静剂/抗焦虑药的医疗用途和非医疗用途(NMPSA)与成年期(35岁)物质使用障碍(SUD)症状之间的纵向关联。
通过自填问卷对多组具有全国代表性的美国高中高年级学生样本(n = 8373)进行调查,并从青少年期(18岁,1976 - 1996年)到成年期(35岁,1993 - 2013年)进行纵向跟踪。
估计有20.1%的青少年报告有过使用处方镇静剂/抗焦虑药的医疗用途或非医疗用途。在报告有使用处方镇静剂/抗焦虑药医疗用途的青少年中,44.9%在18岁时也报告了非医疗用途。基于多变量分析,其中包括18岁时的社会人口统计学和其他物质使用控制因素,与未使用处方镇静剂/抗焦虑药的青少年相比,青少年期使用处方镇静剂/抗焦虑药且无任何非医疗用途历史的医疗用途与成年期的物质使用障碍症状无关。相比之下,与未使用处方镇静剂/抗焦虑药的青少年以及仅报告有使用处方镇静剂/抗焦虑药医疗用途的青少年相比,有使用处方镇静剂/抗焦虑药医疗用途和非医疗用途历史的青少年以及仅报告有非医疗用途的青少年在成年期出现物质使用障碍症状的几率高出两到三倍。
每五名美国高中高年级学生中就有一人报告曾在医疗或非医疗情况下使用过处方镇静剂/抗焦虑药。这项研究提供了令人信服的证据,表明青少年期使用处方镇静剂/抗焦虑药的医疗用途(无任何非医疗用途)与成年期物质使用障碍症状风险增加无关,而青少年期的任何非医疗用途则是成年期物质使用障碍的一个信号。